Please note
This trial is no longer recruiting patients. We hope to add results when they are available.
Head and neck cancers, Laryngeal cancer, Mouth and oropharyngeal cancer, Nasal and paranasal sinus cancer
Closed
Phase 3
This trial is looking at whether having lenvatinib with pembrolizumab works better than pembrolizumab on its own as a treatment for head and neck cancer.
The trial is open to people who have one of following head and neck cancers:
mouth cancer (oral cancer)
cancer of the back of the mouth (oropharyngeal cancer) caused by the (HVP)
cancer of the voice box (laryngeal cancer)
Recruitment start: 13 July 2020
Recruitment end: 29 July 2022
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Kevin Harrington
Merck Sharp & Dohme Ltd
Eisai
Last reviewed: 1 August 2022
CRUK internal database number: 16930
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
